What You Should Know:
- Curebase, a company committed to democratizing access to clinical trials, announced the release of its integrated software and services package for digital therapeutics (DTx) trials that accelerates enrollment and allows sponsors to launch their studies faster.
- Available now, the new Curebase offering includes the first one-stop-shop decentralized clinical trial (DCT) platform bundled with site and trial execution services for the DTx market.
Making
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Paradigm Launches with $203M to Improve Clinical Research Access
What You Should Know:
- Paradigm, a healthcare technology company focused on improving access to clinical research for patients, launched with $203 million in Series A funding.
- Conceived by ARCH Venture Partners, and co-incubated by ARCH and General Catalyst, Paradigm is rebuilding the clinical research ecosystem by creating a technology-forward clinical trial platform that enables equitable access for all patients by enhancing trial efficiency and reducing the barriers to participation
Read More
Boosting Clinical Trial Recruitment Requires Humanity – and Technology
Clinical trials should be a time of promise for better patient outcomes, as they explore new ways to potentially help patients suffering from a variety of conditions. Instead, this phase of treatment development is often met with exasperation as patients, researchers, and drug developers deal with the many barriers to clinical trial recruitment and access.
There are two central – and intrinsically linked – problems with the current state of clinical trial recruitment in the U.S.:
Read More
Caris Life Sciences Raises $400M to Advance AI-Driven Molecular Profiling to Revolutionize Cancer Care
What You Should Know:
- Caris Life Sciences® (Caris), the a molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the company has closed a senior secured term loan providing up to $400M in capital from OrbiMed and Braidwell. With this funding, Caris has raised approximately $1.7 billion in capital since 2018.
- Caris' comprehensive molecular profiling approach precisely analyzes DNA (Whole
Read More
Exec Hires: Greenphire Appoints Owen Newman as the CFO
What You Should Know:
- Greenphire, the global leader in financial lifecycle management for clinical trials, today announced the appointment of Owen Newman as the Chief Financial Officer (CFO).
- Newman brings more than 25 years of financial experience, most recently as CFO of Simeio, a global leader in Identity and Access Management. Newman will report directly to Greenphire's CEO, Jim Murphy.
Owen Newman Bio/Background
Newman is a mature business leader experienced at leading
Read More
7 Life Sciences Executive Predictions to Watch in 2023
Tracy Curley, CFO and interim CEO at iSpecimen
Focusing on the macroeconomic environment, which remains impacted by the lingering COVID-19 pandemic, there continues to be uncertainty about the strength of the global, Asia Pacific, UK and US economies. High-interest rates and a potential recession remain a concern for all market participants. At ISPC, we are closely monitoring the pace of specimen transactions. We believe that this industry can be resilient through a continued economic
Read More
Caris Life Sciences and ConcertAI Partner to Accelerate Drug Development and Novel Research
What You Should Know:
- Caris Life Sciences®(Caris), a molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, an oncology real-world evidence data and AI technology company, announced a unique partnership to align the two companies' oncology capabilities.
- The strategic partnership will create one of the largest translational and clinical
Read More
C2i Genomics & AstraZeneca Partner to Advance Cancer Therapy
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a strategic collaboration with AstraZeneca, a global life sciences and pharmaceutical leader.
- The two companies have collaborated to evaluate the potential of whole-genome minimal residual disease (MRD) testing across solid cancers.
- Expanding on a completion of AstraZeneca’s accelerator BeyondBio SCALE program for start-ups and successful technology validation, C2i Genomics and AstraZeneca
Read More
The Patient Journey Tech Stack: 10 Pharma Predictions for 2023
The complexity of demands on Market Access teams has increased in recent years, between introducing innovative therapies targeting smaller populations and higher bars from Payers and PBMs.
Now, drug manufacturers are bucking up. According to the IQVIA Institute, the prescription abandonment rate has reached 27 percent, or $76 billion annually, in specialty drugs alone. This squandered revenue has led manufacturers to increase their focus on the complex, nuanced patient journey.
As a
Read More
Why The Future of Lateral Flow Testing is Digital
Lateral flow immunoassay tests (or LFTs, for short) have been in use for decades, becoming an indispensable tool within diagnostics’ (Dx) practice, as well as a growing range of applications outside healthcare. LFT's capacity for delivering fast turnaround—rapid detection in less than 20 minutes—from sample to result has made LFTs central to the shift moving triage and primary care closer to the patient at point-of-care (POC) and point-of-need (PON).
Being intuitive for the user,
Read More
